Literature DB >> 19068391

[Histological modifications observed in prostate after preserving treatments for prostate cancer and their impact on Gleason score interpretation].

Vincent Molinié1, W K Mahjoub, André Balaton.   

Abstract

Total prostatectomy remains the main treatment for intermediate risk prostate cancer with a life expectancy greater than 10 years. In other cases non-surgical treatments can be proposed: external radiotherapy (exclusive or combined anti-androgen therapy), brachytherapy with permanent implants, high frequency ultrasounds (HIFU, Ablatherm), cryotherapy or exclusive hormonal treatment. For such patients in case of biological recurrence, prostate biopsies are usually performed in order to affirm the local recurrence. The histological confirmation of persistent tumor is usually required before any treatment: salvage surgery, cryotherapy, and brachytherapy or high intensity focused ultrasound (HIFU). Pathologists must be aware of the histological modifications induced by these different treatments in order to ensure an optimal interpretation of the biopsies. In this review, we describe the modifications observed in the normal prostate and in cancers after these various therapeutic methods, and also after alpha reductase inhibitors proposed as treatment of benign prostate hypertrophy and prostate cancer chemoprevention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19068391     DOI: 10.1016/j.annpat.2008.07.008

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  2 in total

1.  Management of biochemical recurrence after primary localized therapy for prostate cancer.

Authors:  Oussama M Darwish; Ganesh V Raj
Journal:  Front Oncol       Date:  2012-05-23       Impact factor: 6.244

2.  Second salvage treatment for local recurrence of prostate cancer using high-dose-rate brachytherapy: a case report.

Authors:  Audrey Claren; Mathieu Gautier; Julien Feuillade; Alexander Tuan Falk; Jean-Michel Hannoun Levi
Journal:  J Contemp Brachytherapy       Date:  2015-05-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.